Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Favipiravir (T-705) (T-705), an effective and selective RNA-dependent RNA polymerase inhibitor, are applied to treat influenza virus infections.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 41.00 | |
10 mg | In stock | $ 57.00 | |
50 mg | In stock | $ 82.00 | |
100 mg | In stock | $ 124.00 | |
500 mg | In stock | $ 315.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 45.00 |
Description | Favipiravir (T-705) (T-705), an effective and selective RNA-dependent RNA polymerase inhibitor, are applied to treat influenza virus infections. |
Targets&IC50 | RdRP:341 nM. |
In vitro | Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [2] |
In vivo | In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. [1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. [3] |
Cell Research | The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).(Only for Reference) |
Synonyms | T-705, 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide |
Molecular Weight | 157.1 |
Formula | C5H4FN3O2 |
CAS No. | 259793-96-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 12 mg/mL(76.4 mM)
H2O: 5 mg/mL (31.82 mM)
DMSO: 45 mg/mL (286.44 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Favipiravir 259793-96-9 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Others SARS-CoV Influenza Virus DNA/RNA Synthesis inhibit T705 SARS coronavirus T-705 Inhibitor T 705 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide inhibitor